18 results about "Liver weight" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention provides application of an SLC13A3 gene serving as a target spot in preparation of a medicine for treating metabolism-related fatty liver diseases. By constructing an MASLD cell model and an MASLD mouse model with the lesion degree from light to heavy, the expression of the SLC13A3 in the liver tissue and cell model of the metabolism-related fatty liver disease mouse is up-regulated, and the up-regulation multiple is gradually increased along with the increase of the severity of the disease. Animal experiments show that the liver specific knock-down SLC13A3 can significantly relieve weight and liver weight increase, liver fatty degeneration, liver lipid accumulation and liver function impairment accompanied by MASLD, and reduce the expression of adipogenesis genes. The invention provides a new target and a new thought for the development of drugs for treating metabolism-related fatty liver diseases.

The invention relates to application of kaempferol in preparation of drugs, food or health care products for preventing or treating liver cancer related to non-alcoholic fatty liver or non-alcoholic fatty liver. According to the kaempferol disclosed by the invention, the liver weight, the liver weight ratio, the tumor quantity and the maximum diameter of the tumor of a mouse with the non-alcoholic fatty liver-related liver cancer are obviously reduced; in histology, the kaempferol can obviously improve hepatic tissue fatty degeneration and liver lipid droplet density, and improve liver cell inflammation and fibrosis degree; kaempferol can obviously reduce the content of cholesterol serum and cholesterol in the liver of a mouse with non-alcoholic fatty liver-related liver cancer, and can reduce liver injury indexes ALT and AST; the kaempferol can obviously reduce the expression level of mRNA related to liver fibrosis of mice with liver cancer related to non-alcoholic fatty liver.

The invention discloses application of a compound turtle shell liver softening tablet in preparation of a medicine for preventing and / or treating intrahepatic cholangiocarcinoma. The prevention and / or treatment of the intrahepatic cholangiocarcinoma is embodied in at least one of the following aspects: 1) reducing the liver weight of a patient with the intrahepatic cholangiocarcinoma; the invention relates to a pharmaceutical composition for treating intrahepatic cholangiocarcinoma, in particular to a novel pharmaceutical composition for treating intrahepatic cholangiocarcinoma, which has the advantages that the pharmaceutical composition can be used for treating intrahepatic cholangiocarcinoma, reducing liver cell injury and liver fiber hyperplasia of patients with intrahepatic cholangiocarcinoma, regulating cholangiocarcinoma-related protein pathways of the patients with intrahepatic cholangiocarcinoma and inhibiting cancer cell proliferation.

The present invention relates to a composition for preventing or treating metabolic dysfunction-associated liver disease comprising oenotein B, wherein oenotein B reduced elevated liver-related parameters in an animal model of metabolic dysfunction-associated steatotic liver disease, reduced body weight, liver weight, and white adipose tissue to alleviate liver steatosis, reduced inflammation, and inhibited liver fibrosis. Therefore, the composition has the effect of being able to be effectively used for preventing or treating metabolic dysfunction-associated liver disease including liver steatosis, metabolic dysfunction steatohepatitis, and liver fibrosis.

This invention discloses the application of PIEZO1 inhibitors in the preparation of drugs to inhibit liver regeneration. Specifically, this invention relates to the application of the PIEZO1-specific inhibitor Dooku1 in the preparation of drugs to inhibit liver regeneration after hepatectomy. This invention also provides the application of Dooku1 in the preparation of reagents for constructing animal models of liver aplastic disorder. Experiments of this invention show that administration of Dooku1 significantly reduces the liver weight / body weight ratio, inhibits hepatocyte proliferation (significantly decreasing Ki67 positivity rate), and is accompanied by an increase in serum ALT and AST levels, successfully constructing a target-specific and reproducible animal model of liver aplastic disorder. This invention is the first to apply PIEZO1 inhibitors to inhibit liver regeneration, filling the technological gap in negatively regulating liver regeneration through inhibition of the PIEZO1 pathway, and providing potential candidate drugs and intervention strategies for pathological conditions requiring inhibition of abnormal liver hyperplasia after liver transplantation and hepatectomy.

The application discloses application of Rezafetin in preparation of a medicine for treating non-alcoholic fatty liver disease. The application first discovers that the compound has good treatment effect in a non-alcoholic fatty liver disease (NASH) model. Through in-vivo experiments, it is confirmed that in a NASH model mouse, the Rezafetin can significantly reduce pathological characteristics such as liver weight, liver fat level and liver index. Meanwhile, the Rezafetin treatment can significantly reduce the level of serum transaminase (ALT / AST), indicating that the Rezafetin effectively improves liver damage and liver function. The application provides a brand-new and effective drug treatment strategy for clinically treating NASH, and has significant clinical application value and market prospect.

The invention relates to the technical field of poultry breeding and food production, in particular to a lion-head goose overfeeding fat liver weight living body evaluation method. Comprising the following steps: (1) acquiring stearic acid levels of female geese and male geese to obtain quantitative peak area data of stearic acid of the female geese and the male geese; and (2) according to the sex of the lion-head goose, substituting the quantitative peak area data into a formula, and calculating to obtain a female goose liver weight predicted value and a male goose liver weight predicted value. The method disclosed by the invention can be used for non-destructively evaluating the liver development degree and estimating the liver weight after overfeeding. According to the method, a real-time and quantitative key basis is provided for forced feeding regulation and control, an operator can dynamically adjust the forced feeding intensity and the nutrition formula according to individual differences, the problem of excessive forced feeding or insufficient forced feeding caused by a traditional blind feeding mode is effectively avoided, and therefore the animal welfare is guaranteed while the quality uniformity and the superior product rate of the fatty liver are improved.

The application discloses application of an Ilicium fortunei extract in preparation of a product for preventing and treating non-alcoholic fatty liver disease. The Ilicium fortunei extract is prepared through a water extraction-alcohol precipitation-dialysis impurity removal and macroporous resin decolorization process, has a sugar content of 36.23+1.56%, a sugar acid content of 46.00+1.77%, a protein content of 1.03+0.02% and a polyphenol content of 0.07+0.001%. Experimental results show that the extract can significantly reduce the body weight, liver weight and serum transaminase level of a mouse with metabolic disorder induced by a high-fat diet, improve glucose tolerance and insulin resistance, reduce liver steatosis and inflammatory damage, and effectively regulate intestinal flora structure and restore microbial community balance, thereby playing an intervention role on metabolic related fatty liver disease. The application provides a scientific basis for a new use of the Ilicium fortunei extract in prevention and treatment of metabolic related fatty liver disease, and has a good application prospect.

The invention belongs to the field of new application of medicines, and particularly relates to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating obesity and related metabolic diseases of the obesity, in particular to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating the obesity and the related metabolic diseases of the obesity. According to the present invention, 7, 3 ', 4'-Trihydroxyisoflavone is the natural isoflavone compound, and the molecular docking simulation results show that the compound can effectively bind to the potential active site of the GPCPD1 protein; experiments show that the compound can significantly reduce the liver weight and body weight of fat NAFLD model mice induced by high fat diet, reduce intrahepatic lipid droplet deposition and fat vacuolation degeneration, and improve liver function indexes; meanwhile, insulin resistance and abnormal blood glucose metabolism can be relieved. Therefore, the compound can be used for preparing medicines for preventing, relieving or treating obesity and related metabolic disorders, and has important clinical application value.

The invention discloses an application of quercetin and silibinin in preparation of a medicine for promoting liver regeneration. Mouse partial liver resection model experiments prove that quercetin and quercetin and silybin combined medication can remarkably improve the liver weight ratio, liver cell proliferation is further promoted by activating a prostaglandin D2 receptor 1, especially liver regeneration after partial liver resection is promoted, and the effects of repairing liver injury and promoting liver proliferation are achieved.

The application belongs to the field of new use of medicines, and more particularly relates to application of Darapladib in preparation of medicines for preventing and treating metabolic dysfunction related fatty hepatitis. The application firstly finds that after treatment by Darapladib, the liver weight, liver / body ratio, serum total cholesterol, steatosis, ballooning, inflammatory infiltration and collagen deposition of MASH model mice are significantly reduced. The application expands the traditional use of Darapladib in cardiovascular diseases, and provides a new treatment strategy for MASH.

The invention relates to application of opuntia ficus-indica in preparation of drugs, food or health-care products for preventing or treating non-alcoholic steatohepatitis. A non-alcoholic steatohepatitis mouse model fed with methionine and choline lacking high-fat feed finds that the opuntia molluscactus has an obvious effect of resisting the non-alcoholic steatohepatitis; compared with an MCD feed group, the opuntia ficus-indica can obviously reduce the liver weight ratio of mice with non-alcoholic steatohepatitis, compared with a low-dose group and a high-dose group of opuntia ficus-indica, the liver-to-body ratio of the mice is reduced, TC and TG levels in the liver are obviously reduced, and the opuntia ficus-indica can obviously reduce PAOA-induced mouse liver primary cell lipid accumulation and TG levels. In addition, the PAOA-induced mouse liver primary cell BODIPY dyeing fluorescence intensity is obviously reduced, and mouse liver bile acid substitution pathway related metabolic enzyme mRNA and protein expression can be up-regulated.

Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg / day or 900 mg / day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST). Mouse studies showed that miricorilant reduced measures of NAFLD, body weight, liver weight, and liver collagen and galectin-3 levels.

The application discloses application of 3-demethylcolchicine in medicine, and experiment proves that the 3-demethylcolchicine can obviously reduce the body weight and liver weight of NAFLD mice, can obviously reduce the liver injury and liver lipid deposition of the NAFLD mice, and can improve the liver function and abnormal glucose metabolism of the NAFLD, and has a wide application prospect in NAFLD medicine.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, said pharmaceutical composition containing a GLP (Glucagon Like Peptide) analogue as an active ingredient. The GLP analogue of the present invention has been confirmed to be an analogue of GLP-1 and GLP-2, which has been confirmed to have a long in-vivo activity duration due to an increase in the half-life thereof, thereby having an excellent effect in the prevention or treatment of metabolic diseases. Specifically, the peptide disclosed by the invention not only can reduce the weight and fat of an individual, reduce blood sugar, total cholesterol in blood, high-density lipoprotein, low-density lipoprotein and fat factor level in the blood of neutral fat, but also can reduce ASL and AST levels of the liver, the weight of the liver, the degree of hepatic fatty disease and the level of the neutral fat of the liver. From this point, the peptide according to the present invention can be used as an excellent preventive or therapeutic agent for metabolic diseases.

The invention discloses application of dehydrocostus lactone and a medicine for treating steatohepatitis, relates to the technical field of biological medicines, and solves the problems that in the prior art, the application scene of the dehydrocostus lactone is limited, and the application of the dehydrocostus lactone in a complex pathological environment of metabolic dysfunction related steatohepatitis has a technical blank. Dehydrocostus lactone can reduce lipid accumulation, inflammation and fibrosis in liver cells; the weight, liver weight, serum triglyceride content, serum total cholesterol content and insulin resistance level of animals with steatohepatitis are reduced; the content of serum glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, tumor necrosis factor alpha, interleukin 1beta, malondialdehyde and bivalent ferrous ions is reduced, and the content of serum glutathione is increased; the compound can regulate and control lipid metabolism and mitochondrial energy metabolism pathways, reprograms fatty degeneration liver cell energy metabolism phenotypes, and is applied to preparation of drugs for treating steatohepatitis, ferroptosis inhibitors and glutamic oxalacetic transaminase and / or glutamic-pyruvic transaminase inhibitors.

The application discloses application of a Solanum torvum extract in preparation of a medicine for preventing and treating non-alcoholic fatty liver and indications thereof, and the Solanum torvum extract comprises one or both of a Solanum torvum water extract and a Solanum torvum alcohol extract; the application is proved by experiments that the Solanum torvum alcohol extract can obviously reduce the weight of a non-alcoholic fatty liver NAFLD mouse; the Solanum torvum water extract can obviously reduce the inguinal white fat; the Solanum torvum extract can obviously reduce a liver weight / body weight index, a liver triglyceride (TG) content, liver lipid deposition, and liver function damage indexes, i.e., glutamic-oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT). The Solanum torvum extract can also reduce serum triglyceride (TG) and cholesterol (TC) levels of the mouse, improve lipid levels, and therefore has an important role in treating non-alcoholic fatty liver.